Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic
Miguel Malespin, Ciel Harris, Ozdemir Kanar, et al.
Annals of Hepatology (2019) Vol. 18, Iss. 2, pp. 304-309
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States
Vy H. Nguyen, Leslie Y. Kam, Yee Hui Yeo, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2245424-e2245424
Open Access | Times Cited: 38
Hepatitis C Elimination: Opportunities and Challenges in 2023
Gadeer Taha, Levy Ezra, Naim Abu‐Freha
Viruses (2023) Vol. 15, Iss. 7, pp. 1413-1413
Open Access | Times Cited: 25
The Role of the Liver-Specific microRNA, miRNA-122 in the HCV Replication Cycle
Rasika D Kunden, Juveriya Qamar Khan, Sarah Ghezelbash, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5677-5677
Open Access | Times Cited: 55
Epidemiological characteristics and treatment challenges of chronic hepatitis C in the kashi region of xinjiang china: A retrospective investigation from 2018 to 2022
Mingna Li, Kuerbannisa Wulayin, Shasha Ma, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Sleep disturbances among young adult dual users of cigarettes and e-cigarettes: Analysis of the 2020 National Health Interview Survey
Laxmi Poudel, Amrit Baral, Alireza Abdshah, et al.
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0320748-e0320748
Open Access
Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era
Oluwaseun Falade‐Nwulia, Rachel E. Gicquelais, Jacquie Astemborski, et al.
Liver International (2020) Vol. 40, Iss. 10, pp. 2407-2416
Open Access | Times Cited: 32
Clients’ perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters
Carmen L. Masson, J. Konadu Fokuo, A. Anderson, et al.
BMC Infectious Diseases (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 29
Cheminformatics study of some indole compounds through QSAR modeling, ADME prediction, molecular docking, and molecular dynamic simulation to identify novel inhibitors of HCV NS5B protease
Stephen Ejeh, Adamu Uzairu, Gideon Adamu Shallangwa, et al.
Journal of the Indian Chemical Society (2023) Vol. 100, Iss. 3, pp. 100955-100955
Closed Access | Times Cited: 8
HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development
Devis Pascut, Minh Hoang, Như Nhật Quỳnh Nguyễn, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2485-2485
Open Access | Times Cited: 20
Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure
Philip R. Spradling, Yuna Zhong, Anne C. Moorman, et al.
Hepatology Communications (2020) Vol. 5, Iss. 3, pp. 400-411
Open Access | Times Cited: 18
Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels
Alice Zhao, Maximilian Wegener, Ralph Brooks, et al.
Health Promotion Practice (2023) Vol. 24, Iss. 5, pp. 1029-1038
Open Access | Times Cited: 6
Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts
Allison E. Wang, Eric Hsieh, Barbara J. Turner, et al.
Journal of General Internal Medicine (2022) Vol. 37, Iss. 13, pp. 3435-3443
Open Access | Times Cited: 10
Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
Haesuk Park, Hyun Jin Song, Xinyi Jiang, et al.
Hepatology Communications (2020) Vol. 5, Iss. 2, pp. 203-216
Open Access | Times Cited: 15
Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system
Marjan Javanbakht, Roxanne Archer, Jeffrey D. Klausner
PLoS ONE (2020) Vol. 15, Iss. 11, pp. e0241615-e0241615
Open Access | Times Cited: 12
The role of bone morphogenetic proteins in liver fibrosis
Ming Yang, Chunye Zhang
Gastroenterology & Hepatology Open Access (2021) Vol. 12, Iss. 1, pp. 17-20
Closed Access | Times Cited: 8
Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan
Li‐Jen Chang, Han-Cheng Chang, Po‐Yueh Chen, et al.
Medicina (2022) Vol. 58, Iss. 4, pp. 521-521
Open Access | Times Cited: 5
On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017
Christer Frode, Jørn Henrik Vold, Svetlana Skurtveit, et al.
BMJ Open (2020) Vol. 10, Iss. 8, pp. e036355-e036355
Open Access | Times Cited: 7
Engaging the Community in Designing a Hepatitis C Virus Treatment Program for Adults Experiencing Homelessness
Adeline Nyamathi, Sarah A. Wall, Kartik Yadav, et al.
Qualitative Health Research (2021) Vol. 31, Iss. 11, pp. 2069-2083
Open Access | Times Cited: 7
Awareness and Epidemiology of Chronic Hepatitis C Virus Infections in Florida
Emmanuel Thomas, Wei‐Han Cheng, Douglas E. Dylla, et al.
Infectious Diseases and Therapy (2021) Vol. 11, Iss. 1, pp. 451-462
Open Access | Times Cited: 7
Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
Peter Buggisch, Hans Heiken, Stefan Mauss, et al.
PLoS ONE (2021) Vol. 16, Iss. 5, pp. e0250833-e0250833
Open Access | Times Cited: 6
Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States
Haesuk Park, Carolyn Brown, Debbie L. Wilson, et al.
Preventive Medicine Reports (2023) Vol. 32, pp. 102138-102138
Open Access | Times Cited: 2
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders
Xinyi Jiang, Hyun Jin Song, Wei Wang, et al.
Journal of Managed Care & Specialty Pharmacy (2021) Vol. 27, Iss. 7, pp. 873-881
Open Access | Times Cited: 5
Hepatitis C Infection Confirmation and Fewer Visits Contribute to Improving Treatment Rates in a Predominantly African American Health Center
Crisshy Auguste, Rana Khamis, Paul H. Naylor, et al.
Livers (2024) Vol. 4, Iss. 4, pp. 594-600
Open Access
Chemical bioinformatics study of Nonadec-7-ene-4-carboxylic acid derivatives via molecular docking, and molecular dynamic simulations to identify novel lead inhibitors of hepatitis c virus NS3/4a protease
Stephen Ejeh, Adamu Uzairu, Gideon Adamu Shallangwa, et al.
Scientific African (2023) Vol. 20, pp. e01591-e01591
Open Access | Times Cited: 1
Pharmacoinformatics-based strategy in designing and profiling of some Pyrazole analogues as novel hepatitis C virus inhibitors with pharmacokinetic analysis
Stephen Ejeh, Adamu Uzairu, Gideon Adamu Shallangwa, et al.
Egyptian Journal of Basic and Applied Sciences (2023) Vol. 10, Iss. 1, pp. 240-254
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top